Study #2023-0557
A phase Ib study to evaluate the safety, pharmacokinetics, and activity of GDC-1971 in combination with either Osimertinib in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer, or with Cetuximab in patients with metastatic Colorectal Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
GDC-1971, Osimertinib, Cetuximab
Description
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colorectal Cancer, Non-Small Cell Lung Cancer
Study phase:
Phase I
Physician name:
John Paul Shen
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-327-0346
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.